Abstract:Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a poor but heterogeneous prognosis. Although the ALS Functional Rating Scale (ALSFRS) has been most commonly used, the decreases in ALSFRS do not follow a unitary linear trend and may be affected by factors other than disease condition. Group-based trajectory modeling (GBTM) is a method that can take the heterogeneity of declines in ALSFRS into consideration. We analyzed the 16-year trajectory of ALSFRS of patients in China using the GBTM method, and explored possible reasons for differences in the trajectories.Methods: 3,257 patients with sporadic ALS from January 2005 to May 2021 were recruited. ALSFRS scores were the dependent variable in the GBTM. To evaluate whether our results were transferable to other populations, Answer ALS and Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) were used as validation datasets. The baseline characteristics and laboratory indicators in different trajectory groups were compared. A Cox proportional hazards model was used to examine the association between primary outcomes and trajectory groups.Results: A model with four groups (rapid, moderate, slow, and very slow progression) was adopted. The four groups differed in sex (P=0.002), age at onset (P<0.001), diagnostic delay (P<0.001), phenotype (P<0.001), riluzole use (P=0.001), onset site (P<0.001), cerebrospinal fluid (CSF) protein levels (P=0.044), and neutrophil-to-lymphocyte ratio (NLR; P=0.011). Compared with the moderate progression group, the rapid progression group displayed an increased risk of progression to respiratory insufficiency or death (hazard ratio [HR]: 1.66, 95% confidence interval [CI]: 1.41 to 1.97), but the very slow progression group (HR: 0.06, 95% CI: 0.02 to 0.26) had a decreased risk. The trajectory groups with faster progression had a higher NLR and higher total protein in the CSF.Interpretation: This study provides a novel prognosis prediction method using the ALSFRS score trajectory. Notably, the higher NLR and higher total protein in the CSF of the trajectory groups with faster progression suggested that neuroinflammation may play a crucial role in ALS progression.Funding Information: Lu Chen has received the funding from the Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation supported by the Fundamental Research Funds for the Central Universities [Grant number BMU2022PY001]. Shengfeng Wang has received the funding from the Peking University Medicine Fund for World’s Leading Discipline or Discipline Cluster Development supported by the Fundamental Research Funds for the Central Universities [Grant number BMU2021YJ035]. Siyan Zhan has received the funding from the Special Project for Director, China Center for Evidence Based Traditional Chinese Medicine [Grant number 2020YJSZX-2]. Dongsheng Fan has received the fundings from the National Natural Science Foundation of China (NSFC) under Grant [Number 81873784; 82071426].Declaration of Interests: None.Ethics Approval Statement: The protocol was approved by the institutional ethics committee of PUTH (IRB. No 00006761), and written informed consent was obtained from each patient.

Amyotrophic lateral sclerosis established as a multistep process across phenotypes

Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.

Quantifying disease progression in amyotrophic lateral sclerosis

The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration

Clinical Determinants of Disease Progression in Amyotrophic Lateral Sclerosis—A Retrospective Cohort Study

Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data

The impact of age on genetic testing decisions in amyotrophic lateral sclerosis

Early life events may be the first steps on the multistep path to amyotrophic lateral sclerosis

Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis

ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?

Long-Term Longitudinal Progression Pattern of Amyotrophic Lateral Sclerosis: A Trajectory Analysis of a 16-Year Cohort in China

Prognostic Factors and Epidemiology of Amyotrophic Lateral Sclerosis in Southeastern United States

Early-onset, conjugal, twin-discordant, and clusters of sporadic ALS: Pathway to discovery of etiology via lifetime exposome research

Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients

Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis

The genetics and neuropathology of amyotrophic lateral sclerosis

The oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling, and therapeutic implications

Investigating the impact of socioeconomic status on amyotrophic lateral sclerosis

A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials

Multistep modeling applied to a Malaysian ALS registry

Controversies and priorities in amyotrophic lateral sclerosis